ACTRN12622000094774尚未招募1 期
Phase I ascending dose trial of Type 1 Interferon (IFN -1)/ Hyaluronic Acid formulation for the early treatment of SARS-CoV2 infection (COVID-19)
Dr Edmund Lau0 个研究点目标入组 20 人开始时间: 2022年1月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Males or females, aged greater than or equal to 18 years
- •2.Body mass index (BMI) less than or equal to 40.0 kg/m2 and greater than 15kg/m2
- •3.Diagnosis of SARS-CoV2 infection by PCR of nasopharyngeal swab, conducted by a NATA accredited laboratory (or international GLP equivalent) within the past 48hrs
- •4.enrolment within 96 hours from symptom onset (symptoms include: runny nose, headache, sore throat, fever or cough)
- •5.Willing and able to provide informed consent and comply with all study procedures and restrictions and the required visit schedule
- •6.Total Nasal Symptom Score at baseline less than 5
排除标准
- •1.Age < 18 years old
- •2.Concurrent enrolment in other COVID-19 trials involving investigational agents administered within the last 30 days
- •3.Symptoms of pre-existing or intercurrent respiratory tract illness or infection such as pneumonia, bacterial or fungal sinusitis
- •4.Recent sinus surgery (last 2 weeks)
- •5.Suspected or confirmed convalescent COVID-19, defined as any previous positive test in the prior 4 weeks before the most recent positive test
- •6.Inability to operate a nasal spray device
- •7.Inability to provide verbal consent and written consent via eREDCAP
- •8.Known sensitivity/allergy to interferon
- •9.Current use of interferon for another indication
- •10.Major comorbidities increasing risk of study drug including i. Hematologic malignancy, ii. Advanced (stage 4-5) chronic kidney disease or dialysis therapy (eGFR< 29 ml/min), iii. Known history of ventricular arrhythmias iv. Current use of drugs that prolong the QT interval
- •11.Presence or history of substance abuse, including but not limited to cocaine, opioids and marijuana
- •12.Current use of systemic immunosuppressive therapy that cannot be suspended for duration of trial
- •13.Psychiatric disorders that are considered by the treating clinician to be a contraindication to interferon therapy. [i.e., those with mild or well-controlled psychiatric disorders (e.g., mild depression) may be included]
- •14.Any infection requiring IV antibiotics within 4 weeks of Screening, or oral antibiotics within 2 weeks of Screening.
- •15.Females who are pregnant, lactating, or who have a positive pregnancy test.
- •The effects of Gelferon on the unborn child and on the newborn baby are not known. Because of this, participants must not participate in the research if pregnant, trying to become pregnant, breastfeeding, or planning ovum donation.
- •16.Known or suspected hypersensitivity or contraindication to any of the ingredients in the study drug
- •17.Any condition that in the opinion of investigator is a contraindication to the study
- •18.Regular use of topical nasal spray or nasal douching
研究者
相似试验
进行中（未招募）
不适用
A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapysteroid-refractory bronchiolitis obliteransMedDRA version: 13.1Level: PTClassification code 10029888Term: Obliterative bronchiolitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022467-36-DEFreistaat Bayern
招募中
不适用
Randomised clinical trial of interferon rebound therapy for chronic hepatitisB patientschronic hepatitis BJPRN-UMIN000009159Toranomon Hospital100
已完成
不适用
Phase IIa trial of interferon-beta-1a (Avonex) in patients with rheumatoid arthritisRheumatoid arthritis (RA)Musculoskeletal DiseasesArthropathiesISRCTN03626626Biogen Idec Inc. (USA)22
招募中
1 期
A phase 1 dose escalating study of ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours.ACTRN12618001070224Therapim Pty Ltd36
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9